# Exxua (gepirone hydrochloride) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gepirone

> Exxua (gepirone hydrochloride), sponsored by Organon & Co. (OGN), received a complete response letter from the FDA; the decision is dated June 23, 2004.

Data as of November 17, 2026 (snapshot 20261117T232148Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Exxua (gepirone hydrochloride) FDA approved?

Not as of November 18, 2026. Exxua (gepirone hydrochloride), sponsored by Organon & Co. (OGN), received a complete response letter from the FDA; the decision is dated June 23, 2004. FDA complete response letter database: "COMPLETE RESPONSE letter dated 06/23/2004 for NDA 021164 to Organon, Inc.." [Calendar and source filings](https://sec-api.dev/pdufa/gepirone)

Source: FDA complete response letter database, https://api.fda.gov/transparency/crl.json?search=file_name:%22021164Orig1s000OtherActionLtrs.pdf%22 (retrieved 2026-11-17). Last confirmed 2026-11-17T22:20:01.160Z. Cite: https://sec-api.dev/pdufa/gepirone#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Exxua (gepirone hydrochloride) |
| Codes |  |
| Sponsor | Organon & Co. (OGN) https://sec-api.dev/companies/ogn/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 15, 2002: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-17T22:20:01.160Z.
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 03/15/2002 for NDA 021164 to Organon, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22021164Orig1s000OtherActionLtrs.pdf%22

### June 23, 2004: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-17T22:20:01.160Z.
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 06/23/2004 for NDA 021164 to Organon, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22021164Orig1s000OtherActionLtrs.pdf%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gepirone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Exxua (gepirone hydrochloride) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 17, 2026 (snapshot 20261117T232148Z). https://sec-api.dev/pdufa/gepirone

```bibtex
@misc{secapidev_pdufa_gepirone_20261117,
  title        = {Exxua (gepirone hydrochloride) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gepirone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-17, snapshot 20261117T232148Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gepirone_20261117","title":"Exxua (gepirone hydrochloride) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gepirone","issued":{"date-parts":[[2026,11,17]]},"version":"20261117T232148Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
